FrancophonIA/ELRC3.0 huggingface dataset:
English: In addition these patients should continue to be evaluated regularly by their doctor and treatment should be stopped if patients develop heart or circulatory problems, such as uncontrolled high blood pressure or angina.
Estonian: Lisaks peab arst neid patsiente regulaarselt hindama ja ravi tuleb peatada, kui patsiendil tekivad südame- või veresoonkonna probleemid, nagu ravimata hüpertensioon (kõrge vererõhk) või angiin.
English: The CHMP's recommendations were sent to the European Commission, which endorsed them and issued a final legally binding decision valid throughout the EU.
Estonian: Inimravimite komitee soovitused saadeti Euroopa Komisjonile, kes kinnitas need ja andis välja õiguslikult siduva lõpliku otsuse, mis kehtib kogu Euroopa Liidus.
English: • Doctors should review their patients currently on Protelos/Osseor as necessary.
Estonian: • Arstid peavad üle vaatama oma patsiendid, kes saavad praegu Protelost/Osseori.
English: Protelos/Osseor to remain available but with further restrictions
Estonian: Ravimite Protelos/Osseor müügiluba jääb kehtima, aga lisapiirangutega
English: This final EMA recommendation on the use of Protelos/Osseor was based on an analysis of pooled data from randomised studies in around 7,500 post-menopausal women with osteoporosis.
Estonian: Euroopa Ravimiameti lõplik soovitus Protelose/Osseori kasutamise kohta põhineb randomiseeritud uuringute, kus osales ligikaudu 7500 menopausijärgses eas osteoporoosiga naist, koondandmete analüüsil.
English: It is also used to treat severe osteoporosis in men who are at high risk of fracture.
Estonian: Seda kasutatakse ka raske osteoporoosi raviks suure luumurruriskiga meestel.
English: • Doctors should continue to base their decision to prescribe Protelos/Osseor on an assessment of the individual patient's risks.
Estonian: • Arstide otsus Protelost/Osseori määrata peab põhinema iga patsiendi võimalike riskide hindamisel.
English: In deciding on how Protelos/Osseor should be used, the CHMP took into account the PRAC's analysis of its benefits and risks as well as advice from osteoporosis experts that there is a group of patients who could benefit from the medicine.
Estonian: Protelose/Osseori kasutamise otsustamisel arvestas inimravimite komitee ravimiohutuse riskihindamiskomitee analüüsi ravimi kasulikkuse ja riskide kohta ning osteoporoosispetsialistide nõuandeid, et teatud patsientidele võib ravim kasulik olla.
English: Further information on the PRAC recommendation and the background to this review can be found on Agency's website.
Estonian: Lisateave ravimiohutuse riskihindamiskomitee soovituse kohta ja läbivaatamise taustteave on Euroopa Ravimiameti veebisaidil.
English: These final recommendations from the Agency's Committee for Medicinal Products for Human Use (CHMP) come after initial advice from the Pharmacovigilance Risk Assessment Committee (PRAC) to suspend the medicine due to its cardiovascular risk.
Estonian: EMA inimravimite komitee lõplikud soovitused anti pärast ravimiohutuse riskihindamiskomitee algset soovitust ravimi müügiluba kardiovaskulaarse riski tõttu peatada.
English: The first stage of this review was conducted by the Pharmacovigilance Risk Assessment Committee (PRAC), the committee responsible for the evaluation of safety issues for human medicines, which made a set of recommendations.
Estonian: Läbivaatamine esimese etapi viis läbi ravimiohutuse riskihindamiskomitee, kes vastutab inimravimite ohutusprobleemide hindamise eest ja kes andis soovitused ravimi kasutamise kohta.
English: 'The CHMP agreed with the PRAC's overall assessment of the risks of Protelos/Osseor.
Estonian: „Inimravimite komitee nõustus ravimiohutuse riskihindamiskomitee üldise hinnanguga Protelose/Osseori riskide suhtes.
English: The European Medicines Agency has concluded its review of Protelos/Osseor and has recommended further restricting the use of the medicine to patients who cannot be treated with other medicines approved for osteoporosis.
Estonian: Euroopa Ravimiamet lõpetas Protelose/Osseori läbivaatamise ja soovitas ravimi kasutamist täiendavalt piirata patsientidega, keda ei saa ravida teiste osteoporoosi raviks heaks kiidetud ravimitega.
English: The PRAC's recommendations were then sent to the Committee for Medicinal Products for Human Use (CHMP) responsible for all questions concerning medicines for human use, which adopted the Agency's final opinion.
Estonian: Ravimiohutuse riskihindamiskomitee soovitused saadeti seejärel inimravimite komiteele, kes vastutab kõigi inimravimitega seotud probleemide eest ja kes võttis vastu EMA lõpliku arvamuse.
English: In arriving at its conclusions, the CHMP noted that study data showed a beneficial effect in preventing fractures, including in patients at high risk of fracture.
Estonian: Lõpliku otsuse tegemisel märkis inimravimite komitee, et uuringute andmed on näidanud kasulikku mõju murdude ennetamisel, sealhulgas suure luumurruriskiga patsientidel.
English: • You should not take Protelos/Osseor if you have or have had heart or circulatory problems such as stroke, heart attack, or obstruction of the blood flow in the arteries.
Estonian: • Protelost/Osseori ei tohi võtta, kui teil on või on olnud südame- või veresoonkonna probleeme, nagu insult, südamelihaseinfarkt või arteriverevoolu häired.
English: In addition, available data do not show evidence of an increased cardiovascular risk with Protelos/Osseor in patients who did not have a history of heart or circulatory problems.
Estonian: Lisaks ei tõesta saadaolevad andmed kardiovaskulaarsete haiguste suuremat riski, kui ravimeid Protelos/Osseor võtavad patsiendid, kellel ei ole varem olnud südame- või veresoonkonna probleeme.
English: The Committee concluded that given the benefits seen in preventing fractures in patients at high risk, Protelos/Osseor
Estonian: Komitee jõudis järeldusele, et arvestades murdude ennetamise kasulikku mõju suure luumurruriskiga patsientidel, peab Protelos/Osseor olema jätkuvalt saadaval
English: • Your treatment with Protelos/Osseor will be stopped if you develop heart or circulatory problems during treatment.
Estonian: • Ravi Protelose/Osseoriga peatatakse, kui ravi ajal tekivad südame- või veresoonkonna probleemid.
English: Regarding the benefits, the efficacy data showed an effect in preventing fractures, including in patients at high risk of fracture.
Estonian: Efektiivsuse andmed näitasid ravimi kasulikkust luumurdude ennetamisel, sealhulgas suure luumurruriskiga patsientidel.
English: Protelos/Osseor (strontium ranelate) is authorised in the EU to treat severe osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and who are at high risk of fracture (broken bones) to reduce the risk of fractures of the spine and the hip.
Estonian: Ravimitele Protelos/Osseor (strontsiumranelaat) on Euroopa Liidus antud müügiluba raske osteoporoosi (haigus, mis muudab luud hapraks) raviks suure luumurruriskiga menopausijärgses eas naistel, et vähendada lülisamba või puusaliigese murru riski.
English: As recommended in a previous review, patients who have a history of certain heart or circulatory problems, such as stroke and heart attack, must not use the medicine.
Estonian: Nagu ka eelmise läbivaatamise käigus soovitati, ei tohi ravimit kasutada patsiendid, kellel on varem olnud teatud südame- või veresoonkonna probleemid, näiteks insult või südamelihaseinfarkt.
English: Available data do not show evidence of an increased cardiovascular risk in patients without established, current or past history of ischaemic heart disease, peripheral arterial disease or cerebrovascular disease, or in those without uncontrolled hypertension.
Estonian: Olemasolevate andmete põhjal ei ole kardiovaskulaarne risk suurem patsientidel, kellel ei ole diagnoosiga kinnitatud esinev või varem esinenud südame isheemiatõbi, perifeersete arterite haigus, tserebrovaskulaarne haigus või ravimata hüpertensioon.
English: • Protelos/Osseor will only be prescribed for preventing fractures in post-menopausal women and men with severe osteoporosis who have a high risk of fracture and cannot be treated with other medicines approved for osteoporosis.
Estonian: • Protelost/Osseori määratakse luumurdude ennetamiseks ainult raske osteoporoosiga meestel ja menopausijärgses eas naistel, kellel on suur luumurrurisk ja keda ei saa teiste osteoporoosi raviks heaks kiidetud ravimitega ravida.
English: • Protelos/Osseor should be stopped if the patient develops ischaemic heart disease, peripheral arterial disease or cerebrovascular disease, or if hypertension is uncontrolled;
Estonian: • Ravi Protelose/Osseoriga tuleb peatada, kui patsiendil tekib südame isheemiatõbi, perifeersete arterite haigus või ravimata hüpertensioon.
English: The CHMP considered that the cardiovascular risk in patients taking Protelos/Osseor can be managed by restricting its use to patients with no history of heart and circulatory problems and limiting its use to those who cannot take other medicines approved for the treatment of osteoporosis.
Estonian: Inimravimite komitee otsustas, et Protelost/Osseori võtvate patsientide kardiovaskulaarsete haiguste riski saab kontrolli all hoida, kui piirata ravimite kasutust patsientidega, kellel ei ole varem esinenud südame- ega veresoonkonna probleeme ja kes ei saa kasutada teisi osteoporoosi raviks heaks kiidetud ravimeid.
English: • Protelos/Osseor must not be used in patients with established, current or past history of ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease, or those with uncontrolled hypertension;
Estonian: • Protelost/Osseori ei tohi kasutada patsientidel, kellel on diagnoosiga kinnitatud esinev või varem esinenud südame isheemiatõbi, perifeersete arterite haigus ja/või tserebrovaskulaarne haigus või ravimata hüpertensioon.
English: • Protelos/Osseor should only be used to treat severe osteoporosis in postmenopausal women and men at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance;
Estonian: • Protelost/Osseori tohib kasutada ainult raske osteoporoosiga meeste ja menopausijärgses eas naiste raviks, kellel on suur luumurrurisk ja keda ei saa vastunäidustuste või talumatuse tõttu ravida teiste osteoporoosi raviks heaks kiidetud ravimitega.
English: There was also an unvaccinated control group.
Estonian: Uuringus oli ka vaktsineerimata kontrollrühm.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Eryseng Parvo on 8 July 2014.
Estonian: Euroopa Komisjon andis Eryseng Parvo müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 8. juulil 2014.
English: For swine erysipelas two laboratory studies were conducted.
Estonian: Sigade erüsiipeli uurimiseks viidi läbi kaks laboratoorset uuringut.
English: The most common side effect (seen in more than 1 in 10 pigs) with Eryseng Parvo is mild to moderate inflammation at the injection site which typically resolves within four days but in some cases may persist for up to 12 days post-vaccination.
Estonian: Eryseng Parvo kõige sagedam kõrvalnäht (ilmnes enam kui 1 seal 10st) on kerge või mõõdukas põletik süstekohal, mis tavaliselt möödub nelja päeva jooksul, kuid võib mõnel juhul püsida kuni 12 päeva pärast vaktsineerimist.
English: Pigs were challenged with parvovirus at day 40 of pregnancy and then euthanized (humanely killed) at day 90 of pregnancy.
Estonian: Sead nakatati tiinuse 40. päeval parvoviirusega ja surmati eutanaasia teel (humaanne tapmine) tiinuse 90. päeval.
English: The parvovirus study showed that Eryseng Parvo protected 100% of the foetuses whilst 89% of foetuses were mummified in the control group.
Estonian: Parvoviiruse uuring näitas, et Eryseng Parvo kaitses looteid 100%, samas kui kontrollrühmas oli 89% loodetest mumifitseerunud.
English: The second laboratory study involved 15 gilts which were vaccinated according to the basic vaccination schedule with a booster dose six months later.
Estonian: Teine laboratoorne uuring hõlmas 15 nooremist, keda vaktsineeriti põhivaktsineerimisskeemi kohaselt kuue kuu pärast korduvannusega.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Eryseng Parvo exceed the risks for the approved indication and recommended that Eryseng Parvo be given a marketing authorisation.
Estonian: Veterinaarravimite komitee järeldas, et heakskiidetud näidustustel on Eryseng Parvo kasulikkus suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
English: For porcine parvovirus a laboratory study was conducted involving three groups of 11 gilts (female pigs that have not yet had piglets) vaccinated with different concentrations of porcine parvovirus.
Estonian: Sigade parvoviiruse uurimiseks viidi läbi laboratoorne uuring, milles osales kolm 11 nooremisest (emased sead, kellel ei ole veel põrsaid olnud) koosnevat rühma, keda vaktsineeriti eri kontsentratsioonis sigade parvoviirusega.
English: The first study involved 40 pigs; 30 pigs were vaccinated with two doses, separated by three weeks, while a control group of 10 pigs received placebo (dummy treatment).
Estonian: Esimene uuring viidi läbi 40 seaga; 30 siga vaktsineeriti kolmenädalase vahega kahe annusega, 10 seast koosnev kontrollrühm sai platseebot (näiv ravim).
English: The withdrawal period for Eryseng Parvo is zero days.
Estonian: Eryseng Parvo keeluaeg on null päeva.
English: Eryseng Parvo is a veterinary vaccine that contains inactivated (killed) porcine parvovirus and Erysipelothrix rhusiopathiae bacteria.
Estonian: Eryseng Parvo on veterinaarvaktsiin, mis sisaldab sigade inaktiveeritud (hävitatud) parvoviirust ja Erysipelothrix rhusiopathiae baktereid.
English: For swine erysipelas, the first laboratory study showed that 90% (27 out of 30) of vaccinated pigs were protected against Erysipelothrix rhusiopathiae serotype 1 remaining free of specific skin lesions whilst 93% (28 out of 30) of vaccinated pigs were protected against Erysipelothrix rhusiopathiae serotype 2 remaining free of specific skin lesions.
Estonian: Sigade erüsiipeli kohta näitas esimene laboratoorne uuring, et 90% vaktsineeritud sigadest (27 siga 30st) oli kaitstud Erysipelothrix rhusiopathiae serotüübi 1 eest, sest neil ei tekkinud spetsiifilisi nahakahjustusi, samas kui 93% vaktsineeritud sigadest (28 siga 30st) oli kaitstud Erysipelothrix rhusiopathiae serotüübi 2 eest, sest neil ei tekkinud spetsiifilisi nahakahjustusi.
English: The measure of effectiveness was absence of porcine parvovirus and anti-porcine parvovirus antibodies in the foetuses.
Estonian: Efektiivsuse näitaja oli sigade parvoviiruse ja sigade parvoviiruse vastaste antikehade puudumine loodetes.
English: Eryseng Parvo contains an adjuvant (aluminium hydroxide, DEAE-dextran and ginseng) to enhance the immune response.
Estonian: Eryseng Parvo sisaldab immuunvastuse tugevdamiseks adjuvanti (alumiiniumhüdroksiid, DEAEdekstraan ja ženšenn).
English: Eryseng Parvo is a vaccine.
Estonian: Eryseng Parvo on vaktsiin.
English: Pigs were vaccinated with two doses at an interval of three weeks, with the second dose given three to four weeks before mating.
Estonian: Sigu vaktsineeriti kolmenädalase vahega kahe annusega, teine annus manustati kolm kuni neli nädalat enne paaritamist.
English: It contains a strain of porcine parvovirus called NADL-2 and a strain of Erysipelothrix rhusiopathiae called R32E11.
Estonian: Vaktsiin sisaldab sigade parvoviiruse tüve NADL-2 ja Erysipelothrix rhusiopathiae tüve R32E11.
English: The second laboratory study showed 93% (14 out of 15) pigs were protected against challenge with Erysipelothrix rhusiopathiae serotypes 1 and 2.
Estonian: Teine laboratoorne uuring näitas, et 93% sigadest (14 siga 15st) oli kaitstud nakatumise eest Erysipelothrix rhusiopathiae serotüüpidega 1 ja 2.
English: In the future, if the animals are exposed to porcine parvovirus and Erysipelothrix rhusiopathiae bacteria, the immune system will be able to respond more quickly.
Estonian: Kui loomad puutuvad hiljem sigade parvoviiruse ja Erysipelothrix rhusiopathiae bakteritega uuesti kokku, tekivad antikehad kiiremini.
English: Eryseng Parvo is used to protect embryonic and foetal (unborn) piglets against porcine parvovirus infection via the placenta.
Estonian: Eryseng Parvot kasutatakse sündimata põrsaste (embrüode ja loodete) kaitsmiseks sigade parvoviirusesse nakatumise eest platsenta kaudu.
English: Why has Eryseng Parvo been approved?
Estonian: Miks Eryseng Parvo heaks kiideti?
English: Other information about Eryseng Parvo:
Estonian: Muu teave Eryseng Parvo kohta
English: The measure of effectiveness was the percentage of vaccinated pigs free from specific (diamond shaped) skin lesions at the challenge site.
Estonian: Efektiivsuse näitaja oli nakatumiskohal spetsiifiliste nahakahjustusteta (teemandikujulised kahjustused) vaktsineeritud sigade osakaal.
English: Porcine parvovirosis and swine erysipelas vaccine (inactivated)
Estonian: sigade parvoviiruse ja sigade erüsiipeli vaktsiin (inaktiveeritud)
English: How does Eryseng Parvo work?
Estonian: Kuidas Eryseng Parvo toimib?
English: When Eryseng Parvo is given to pigs the animals' immune system recognises the virus and bacteria as ‘foreign' and makes antibodies against them.
Estonian: Kui sigadele manustatakse Eryseng Parvot, peab immuunsüsteem vaktsiinis sisalduvaid viirust ja baktereid võõraks ja tekitab nende vastu antikehi.
English: What is Eryseng Parvo?
Estonian: Mis on Eryseng Parvo?
English: This will help protect them against porcine parvovirus and swine erysipelas.
Estonian: See aitab loomi sigade parvoviiruse ja sigade erüsiipeli eest kaitsta.
English: What is the risk associated with Eryseng Parvo?
Estonian: Mis riskid Eryseng Parvoga kaasnevad?
English: Eryseng Parvo is also used to protect male and female pigs against swine erysipelas caused by Erysipelothrix rhusiopathiae, serotype 1 and serotype 2.
Estonian: Eryseng Parvot kasutatakse ka kultide ja emiste kaitsmiseks Erysipelothrix rhusiopathiae bakteri serotüüpide 1 ja 2 põhjustatud sigade erüsiipeli eest.
English: What is Eryseng Parvo used for?
Estonian: Milleks Eryseng Parvot kasutatakse?
English: Porcine parvovirus causes infertility, still births and small litters in sows (female pigs that have had piglets).
Estonian: Sigade parvoviirus põhjustab emistel (emased sead, kellel on olnud põrsad) viljatust, surnult sünde ja väikesi pesakondi.
English: What benefit has Eryseng Parvo shown during the studies?
Estonian: Milles seisneb uuringute põhjal Eryseng Parvo kasulikkus?
English: How has Eryseng Parvo been studied?
Estonian: Kuidas Eryseng Parvot uuriti?
English: Eryseng Parvo is available as a suspension for injection.
Estonian: Vaktsiini Eryseng Parvo turustatakse süstesuspensioonina.
English: Velmetia is taken twice a day.
Estonian: Velmetiat võetakse kaks korda ööpäevas.
English: The full EPAR for Velmetia can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Velmetia kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the EU for Velmetia on 16 July 2008.
Estonian: Euroopa Komisjon andis Velmetia müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 16. juulil
English: Other information about Velmetia
Estonian: Muu teave Velmetia kohta
English: The results of three further studies were used to support the use of Velmetia.
Estonian: Velmetia kasutamise toetamiseks kasutati kolme muu uuringu tulemusi.
English: The company presented the results of three studies of Januvia/Xelevia to support the use of Velmetia in patients who were not satisfactorily controlled on their existing metformin treatment.
Estonian: Ettevõte esitas Januvia/Xelevia kolme uuringu tulemused, et toetada Velmetia kasutamist patsientidel, kelle senine metformiiniravi ei andnud rahuldavaid tulemusi.
English: The most common side effect with Velmetia (seen in between 1 and 10 patients in 100) is nausea (feeling sick).
Estonian: Velmetia kõige sagedam kõrvalnäht (esinenud 1-10 patsiendil 100st) on iiveldus.
English: The CHMP decided that Velmetia's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Velmetia kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Velmetia sitagliptin / metformin hydrochloride
Estonian: Velmetia sitagliptiin/metformiinvesinikkloriid
English: For more information about treatment with Velmetia, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Velmetiaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The company carried out additional studies to show that the active substances in Velmetia are absorbed by the body in the same way as the two medicines given separately.
Estonian: Ettevõte tegi ka lisauuringud, et määrata kindlaks, kas Velmetia toimeained imenduvad organismis samal viisil kui kumbki aine eraldi manustatuna.
English: Velmetia is a medicine that contains two active substances, sitagliptin and metformin hydrochloride.
Estonian: Velmetia on ravim, mis sisaldab kaht toimeainet, sitagliptiini ja metformiinvesinikkloriidi.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Velmetia.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Why has Velmetia been approved?
Estonian: Miks Velmetia heaks kiideti?
English: In the first of the three further studies, Velmetia was more effective than metformin or sitagliptin alone.
Estonian: Kolmest lisauuringust esimeses oli Velmetia efektiivsem kui ainult metformiin või sitagliptiin.
English: What is Velmetia?
Estonian: Mis on Velmetia?
English: What is the risk associated with Velmetia?
Estonian: Mis riskid Velmetiaga kaasnevad?
English: This is a summary of the European public assessment report (EPAR) for Velmetia.
Estonian: See on ravimi Velmetia Euroopa avaliku hindamisaruande kokkuvõte.
English: Velmetia was more effective than metformin alone.
Estonian: Velmetia oli efektiivsem kui ainsa ravimina kasutatud metformiin.
English: If Velmetia is taken with a sulphonylurea or insulin, the dose of the sulphonylurea or insulin may need to be lowered, to avoid hypoglycaemia (low blood sugar levels).
Estonian: Kui Velmetiat võetakse koos sulfonüüluurearavimiga või insuliiniga, võib olla vaja vähendada sulfonüüluurearavimi või insuliini annust, et ennetada hüpoglükeemiat (normaalsest väiksem glükoosisisaldus veres).
English: Velmetia must not be used in people who are hypersensitive (allergic) to sitagliptin, metformin or any of the other ingredients.
Estonian: Velmetiat ei tohi kasutada patsiendid, kes on sitagliptiini, metformiini või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: The active substances in Velmetia, sitagliptin and metformin hydrochloride, each have a different mode of action.
Estonian: Velmetia toimeained sitagliptiin ja metformiinvesinikkloriid on kumbki eri toimega.
English: For the full list of all side effects reported with Velmetia, see the package leaflet.
Estonian: Velmetia kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What benefit has Velmetia shown during the studies?
Estonian: Milles seisneb uuringute põhjal Velmetia kasulikkus?
English: The first included 1,091 patients who were not satisfactorily controlled on diet and exercise alone and compared the effect of Velmetia with that of metformin or sitagliptin alone.
Estonian: Esimeses uuringus osales 1091 patsienti, kelle seisundit ei saanud rahuldavalt reguleerida üksnes dieedi ja füüsilise koormusega, ja selles võrreldi Velmetia toimet ainult metformiini või sitagliptiini toimega.